Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent quarter, what's ...

Teva Pharmaceutical Industries reported on Wednesday a higher-than-expected rise in third-quarter profit, helped by strong ...

In its third quarter, Teva booked revenue of $4.48 billion. That was 3% higher year over year, and much of that growth came ...

Even with Inflation Reduction Act (IRA)-related pressure looming for its top product, Teva Pharmaceuticals is continuing to ...

Teva Q3 revenue rose to $4.48 billion, beating estimates, as Austedo and Ajovy boosted growth; 2025 EPS outlook now ...

Teva Pharmaceutical (TEVA) stock surges as the company posts better than expected Q3 2025 results and raises the midpoint of ...

Teva shares jumped 12% after Q3 earnings beat estimates, driven by strong branded drug sales led by Austedo and solid guidance for 2025.

Teva Pharmaceuticals has a new game plan for raising awareness of tardive dyskinesia (TD). | Teva Pharmaceuticals has a new ...

Teva Pharmaceutical Industries Limited ( ($TEVA) ) has released its Q3 earnings. Here is a breakdown of the information Teva Pharmaceutical ...

For an accessible version of this Press Release, please visit reports revenues of $4.5 billion in the third quarter of ...

Toast Inc (NYSE: TOST) gained 9.3% to $39.00 after the company reported better-than-expected quarterly financial results. Also, Morgan Stanley maintained an Overweight rating on the stock and raised ...

Teva Pharmaceutical Industries Ltd ADR stock has reached a new 52-week high, touching 23.07 USD. This milestone reflects a significant upward trend in the company’s stock performance over the past ...